Understanding immune and brain cell behavior in Alzheimer's disease using advanced models.
Elucidating Immune and Microglial Dynamics in Alzheimer's Disease with Advanced Organoid Models.
This study is looking at how certain brain and immune cells act in Alzheimer's disease and is testing special lab-grown brain models to see if certain treatments can help these cells fight the disease better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11032869 on NIH RePORTER |
What this research studies
This research investigates how immune cells and microglia, a type of brain cell, behave in Alzheimer's disease by using advanced organoid models that mimic the human brain. The approach involves conditioning mesenchymal stem cells with stimuli that simulate Alzheimer's conditions to enhance their regenerative properties. Researchers will analyze the secreted factors from these cells to identify those that may help combat the pathology associated with Alzheimer's. The study employs various biochemical methods to assess the effectiveness of these factors in cellular models of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk for developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with Alzheimer's disease.
How similar studies have performed: Other research has shown promise in using stem cell therapies for neurodegenerative diseases, indicating potential for success with this approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Burgess, Jeremy Daniel — Univ of North Carolina Chapel Hill
- Study coordinator: Burgess, Jeremy Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.